Skip to main content
    K

    Keros Therapeutics Inc (KROS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.31
    +1.28 (+12.76%)

    Market Cap: $196.83M

    Last updated: Nov 17, 2026 at 4:34 PM ET

    Keros Therapeutics Inc (KROS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Keros Therapeutics (KROS) has a market cap of $196.83M. Its share count is down 51.05% from a year earlier. It kept -151.43% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$196.83M
    Latest price (Nov 17, 2026)$11.31

    Key Dates

    The next earnings report is expected on Mar 2, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 2, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.43% in the quarter ended Sep 30, 2026 and shrank 27.27% a year over 2 years.

    Shares Outstanding19.89M
    Shares Change (YoY)-51.05%
    Shares Change (QoQ)+0.43%
    Share Count Growth (2Y CAGR)-27.27%

    Valuation Ratios

    Sales and book value multiples are 5.5x and 0.8x. Its year-end P/S ranged from 3.4x to 177.7x from 2021 to 2025.

    P/S Ratio5.5x
    Forward P/S4.8x
    P/B Ratio0.8x

    Valuation history and multiples

    Price Statistics

    The stock is down 34.47% over 52 weeks and trades 2.72% above its 50-day average.

    Beta (1Y)1.19
    52-Week Change-34.47%
    1-Month Change+2.26%
    3-Month Change+1.89%
    6-Month Change+14.13%
    5-Year Change-73.54%
    Total Return (1Y)-34.47%
    Total Return (3Y CAGR)-27.98%
    Total Return (5Y CAGR)-28.77%
    Return vs SPY (1Y)-47.11%
    Max Drawdown (1Y)-58.01%
    Max Drawdown (3Y)-86.99%
    Sharpe Ratio (1Y)-0.83
    Correlation with SPY (1Y)0.31
    50-Day Average$11.01
    200-Day Average$11.55
    52-Week Range$8.98 to $22.55
    RSI (14 Days)58.1
    Average Volume (20 Days)202.11K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 18.14x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio18.14x
    Quick Ratio18.14x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -22.12% over the last 12 months, against a 5-year average of -22.40%.

    Return on Equity (ROE)-22.12%
    Return on Assets (ROA)-20.08%
    ROE (5Y Average)-22.40%
    ROA (5Y Average)-20.63%
    ROIC (5Y Average)20.94%
    Asset Turnover0.08x
    Receivables Turnover4.08x

    Scores

    KROS has an Altman Z-Score of 2.81, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score2.81
    Altman Z ZoneGrey
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $40.76M over the last 12 months is down 83.48% from the 12 months before.

    Revenue$40.76M
    Revenue Growth (YoY)-83.48%
    Gross Profit$40.76M
    Operating Income-$73.27M
    Pretax Income-$62.47M
    Net Income-$61.73M
    Reported EPS (TTM)-$2.82

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 90.80% of the $307.37M in total assets.

    Cash and Equivalents$259.46M
    Total Debt$0
    Net Cash$259.46M
    Net Cash Per Share$13.05
    Working Capital$271.78M
    Shareholder Equity$279.10M
    Book Value Per Share$14.03
    Total Assets$307.37M
    Total Liabilities$28.27M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $421.00K of capital spending, operating cash flow left -$48.27M of free cash flow.

    Operating Cash Flow-$47.85M
    Capital Expenditures$421.00K
    Free Cash Flow-$48.27M
    FCF Per Share-$2.43
    Depreciation and Amortization$1.59M
    Share Repurchases$382.21M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -179.75%.

    Gross Margin100.00%
    Operating Margin-179.75%
    Pretax Margin-153.25%
    Net Margin-151.43%
    FCF Margin-118.43%

    Growth

    Book Value Per Share Growth (2Y CAGR)-14.79%
    Tangible Book Per Share Growth (2Y CAGR)-14.79%

    Revenue and profit by year

    Dividends and Yields

    KROS does not pay a dividend. Its free cash flow yield is -21.46%.

    FCF Yield-21.46%
    Buyback Yield169.94%
    Shareholder Yield169.94%

    Peer Position

    Against 7 similar companies, KROS has the 6th highest P/S.

    P/S Ratio5.5x vs 11.8x median
    Revenue Growth (Trailing 4 Quarters, YoY)-83.48% vs -68.74% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -76.29% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-76.29%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About KROS

    What is KROS's market cap?

    Keros Therapeutics has a market cap of $196.83M.

    How many shares of KROS are outstanding?

    Keros Therapeutics has 19.89M shares outstanding. The count is down 51.05% from a year earlier.

    Does KROS pay a dividend?

    No. Keros Therapeutics does not pay a dividend.

    How much debt does KROS have?

    Keros Therapeutics has $0 of total debt and $259.46M of cash and equivalents, a net cash position of $259.46M.